Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(16):1177; doi:10.1093/jnci/dji271
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Elana Hayasaka, Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Erlotinib May Be an Effective Treatment for Advanced Lung Cancer

Previously treated patients with advanced lung cancer may have a treatment option in erlotinib (Tarceva), according a recent study, which indicated that the drug may prolong survival for these patients.

In a randomized trial involving 731 patients with non–small-cell lung cancer (NSCLC), this study found that the group taking erlotinib survived an average of 6.7 months, compared with 4.7 months in the placebo group. Moreover, 31% of the 488 . . . [Full Text of this Article]

Cochrane Collaboration Publishes Two Systematic Reviews on Cancer

FDA Accepts Modified Qualified Health Claim for Anticancer Benefit of Green Tea

FDA Commissioner Confirmed by Senate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?